BRPI0813966A8 - Usos de mdl-1 - Google Patents

Usos de mdl-1

Info

Publication number
BRPI0813966A8
BRPI0813966A8 BRPI0813966A BRPI0813966A BRPI0813966A8 BR PI0813966 A8 BRPI0813966 A8 BR PI0813966A8 BR PI0813966 A BRPI0813966 A BR PI0813966A BR PI0813966 A BRPI0813966 A BR PI0813966A BR PI0813966 A8 BRPI0813966 A8 BR PI0813966A8
Authority
BR
Brazil
Prior art keywords
cdm
mdl
antagonists
methods
relates
Prior art date
Application number
BRPI0813966A
Other languages
English (en)
Inventor
E Bigler Michael
J Cua Daniel
Joyce-Shaikh Barbara
H Phillips Joseph
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Publication of BRPI0813966A2 publication Critical patent/BRPI0813966A2/pt
Publication of BRPI0813966A8 publication Critical patent/BRPI0813966A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

USOS DE MDL-1. A presente invenção refere-se a métodos para tratamento de distúrbios de reabsorção óssea com antagonistas de MDL-1.
BRPI0813966A 2007-06-29 2008-06-24 Usos de mdl-1 BRPI0813966A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94731407P 2007-06-29 2007-06-29
PCT/US2008/068042 WO2009006112A1 (en) 2007-06-29 2008-06-24 Mdl-1 uses

Publications (2)

Publication Number Publication Date
BRPI0813966A2 BRPI0813966A2 (pt) 2015-01-06
BRPI0813966A8 true BRPI0813966A8 (pt) 2016-02-10

Family

ID=39712082

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813966A BRPI0813966A8 (pt) 2007-06-29 2008-06-24 Usos de mdl-1

Country Status (10)

Country Link
US (2) US20100221252A1 (pt)
EP (1) EP2176294B1 (pt)
JP (2) JP5171948B2 (pt)
CN (1) CN101802011A (pt)
AU (1) AU2008270710A1 (pt)
BR (1) BRPI0813966A8 (pt)
CA (1) CA2691618A1 (pt)
ES (1) ES2540854T3 (pt)
WO (1) WO2009006112A1 (pt)
ZA (1) ZA201000393B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
WO2011053630A1 (en) * 2009-10-30 2011-05-05 Schering Corporation Uses of a mammalian cytokine
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
EP2675467A4 (en) * 2011-02-18 2014-06-25 Merck Sharp & Dohme USE OF MDL-1 ANTAGONISTS FOR THE TREATMENT OF SPONDYLARTHROPATHY
WO2013043516A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Mdl-1 ligand
AU2012323849B2 (en) 2011-10-13 2017-04-20 EyePoint, Inc. Treatment of ocular disease
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
ES2732712T3 (es) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
RS67639B1 (sr) 2011-11-16 2026-02-27 Boehringer Ingelheim Int Anti il-36r antitela
KR102568808B1 (ko) 2014-04-07 2023-08-18 추가이 세이야쿠 가부시키가이샤 면역활성화 항원 결합 분자
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
EA202192405A1 (ru) 2019-03-08 2022-01-13 Бёрингер Ингельхайм Интернациональ Гмбх Составы антител против il-36r
PH12021552960A1 (en) 2019-07-10 2022-07-25 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CN115779071B (zh) * 2022-11-04 2024-12-24 济宁医学院附属医院 Mdl-1在制备缺血性脑卒中后脑保护药物中的应用
TW202517686A (zh) * 2023-07-13 2025-05-01 大陸商深圳澤安生物醫藥有限公司 多特異性抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416973B1 (en) * 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
WO2005027848A2 (en) * 2003-09-19 2005-03-31 Barnes-Jewish Hospital Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
AR059193A1 (es) * 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
WO2008133857A1 (en) * 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies

Also Published As

Publication number Publication date
US20120177647A1 (en) 2012-07-12
ZA201000393B (en) 2014-03-26
US20100221252A1 (en) 2010-09-02
JP2012233008A (ja) 2012-11-29
CA2691618A1 (en) 2009-01-08
EP2176294A1 (en) 2010-04-21
AU2008270710A1 (en) 2009-01-08
EP2176294B1 (en) 2015-05-20
BRPI0813966A2 (pt) 2015-01-06
JP5171948B2 (ja) 2013-03-27
WO2009006112A1 (en) 2009-01-08
CN101802011A (zh) 2010-08-11
ES2540854T3 (es) 2015-07-14
JP2010532369A (ja) 2010-10-07

Similar Documents

Publication Publication Date Title
CR20110103A (es) Heteroarilos sustituidos
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
BRPI0922384A2 (pt) "manipulador de suprimento para equipamento".
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
BR112012013260A2 (pt) dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
DE602007012072D1 (de) Orantagonisten
BR112012017051A2 (pt) método para diminuir a imunogenicidade
DE112007000518A5 (de) Anlage zur Erzeugung von Elektrizität
NI200900148A (es) COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33536A
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
BRPI1006730A2 (pt) biomateriais de fosfato de cálcio com gálio
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
BRPI0716532A2 (pt) compostos azabicÍclios como inidores de reabsorÇço de monoaminas
IL206359A0 (en) Sulfonamides as orexin antagonists
EP2253206A4 (en) COMPOSITION FOR COMBATING PLANT DISEASES
BR112012004902A2 (pt) compostos de revestimentos flexível com preponderância de composição mineral
SE0800742L (sv) Vikttäcke
PA8782301A1 (es) Tratamiento de leucemia resistente al imatinte

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.